or Try an Advanced Search...

    Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 9.32 2.60% 0.24
    ENTA closed down 3.61 percent on Wednesday, November 20, 2024, on 1.16 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ENTA trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 2.60%
    Wide Bands Range Expansion 2.60%
    Below Lower BB Weakness 2.60%
    Lower Bollinger Band Touch Weakness 2.60%
    Oversold Stochastic Weakness 2.60%
    Doji - Bullish? Reversal -1.10%
    Lower Bollinger Band Walk Weakness -1.10%
    Earnings Movers Other -1.10%
    Wide Bands Range Expansion -1.10%
    Gapped Down Weakness -1.10%
    Older End-of-Day Signals for ENTA ...

       Recent Intraday Alerts

    Alert Time
    Up 2% 19 minutes ago
    60 Minute Opening Range Breakout 37 minutes ago
    3x Volume Pace about 3 hours ago
    Down 3% about 3 hours ago
    Down 2 % about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ENTA Chart by TradingView
    Basic chart:

    Profile

    Enanta Pharmaceuticals, Inc. Description

    Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Infectious Diseases Chemical Compounds Infection Medical Research Viruses Hepatitis C Hepatitis C Virus HCV Cyclophilin Staphylococcus Aureus Treatment Of Hepatitis Cyclopropanes Methicillin HCV Infection Pyrrolidines

    Is ENTA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 27 The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable
    Oct 19 Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline
    Oct 17 Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares
    Oct 2 Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
    Sep 27 J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
    Sep 26 Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study
    Sep 26 Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
    Sep 3 Enanta Pharmaceuticals to Participate in Investor Conferences in September
    Aug 9 Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now?
    Aug 7 Enanta Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
    See more ENTA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.8
    52 Week Low 8.51
    Average Volume 156,134
    200-Day Moving Average 13.06
    50-Day Moving Average 11.20
    20-Day Moving Average 10.83
    10-Day Moving Average 10.21
    Average True Range 0.52
    RSI (14) 23.66
    ADX 24.86
    +DI 11.64
    -DI 34.69
    Chandelier Exit (Long, 3 ATRs) 11.81
    Chandelier Exit (Short, 3 ATRs) 10.54
    Upper Bollinger Bands 12.51
    Lower Bollinger Band 9.15
    Percent B (%b) -0.02
    BandWidth 31.09
    MACD Line -0.58
    MACD Signal Line -0.37
    MACD Histogram -0.2172
    Fundamentals Value
    Market Cap 192.1 Million
    Num Shares 21.2 Million
    EPS -6.57
    Price-to-Earnings (P/E) Ratio -1.38
    Price-to-Sales 3.55
    Price-to-Book 1.36
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.70
    Resistance 3 (R3) 9.73 9.56 9.59
    Resistance 2 (R2) 9.56 9.40 9.54 9.56
    Resistance 1 (R1) 9.32 9.31 9.24 9.29 9.52
    Pivot Point 9.15 9.15 9.11 9.13 9.15
    Support 1 (S1) 8.91 8.99 8.82 8.87 8.64
    Support 2 (S2) 8.74 8.90 8.72 8.60
    Support 3 (S3) 8.50 8.74 8.57
    Support 4 (S4) 8.46